BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 16584602)

  • 1. [Effects of sensitized donor lymphocyte infusion on the chimerism and graft-versus-host disease after nonmyeloablative allogeneic stem cell transplantation].
    Chen BA; Zhang Y; Ding JH; Bi YZ; Zhao G; Gao C; Sun YY; Sun XM; Wang J; Chen NN; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):102-6. PubMed ID: 16584602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
    Mapara MY; Kim YM; Marx J; Sykes M
    Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selective elimination of alloreactive donor lymphocytes by using TBI and cyclophosphamide].
    Chen BA; Dong WM; Ding JH; Sun XM; Deng XJ; Zhang Y; Bi YZ; Zhao G; Gao C; Sun YY; Wang J; Cheng J; Schmitt M; Schmitt A
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):332-6. PubMed ID: 17493342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
    Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
    Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
    Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on graft-versus-leukemia effects of donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation].
    Du B; Li D; Xu K
    Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):403-7. PubMed ID: 11718089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of intra-bone marrow infusion of donor lymphocytes on development of graft-versus-host disease and level of IL-4 and IFN-gamma in peripheral blood].
    Bi YZ; Zeng DX; Sheng GF; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1538-40. PubMed ID: 20030942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Establishment of nonmyeloablative allogeneic stem cell transplantation model in H-2 haploidentical mice and its related study].
    Li JJ; Zhang Y; Zhang MW; Hou CM; Wu Y; Mao N; Ai HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Oct; 12(5):655-60. PubMed ID: 15498129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL
    Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.